Ubs Group Ag Celldex Therapeutics, Inc. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 841,246 shares of CLDX stock, worth $22.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

841,246

Previous 1,468,240 42.7%

Holding current value

$22.9 Million

Previous $26.6 Million 35.76%

% of portfolio

0.0%

Previous 0.01%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$15.13 - $21.65 $9.49 Million - $13.6 Million	-626,994 Reduced 42.7%	841,246 $17.1 Million
Q1 2025 May 13, 2025	BUY	$18.15 - $27.6 $19.6 Million - $29.8 Million	1,078,443 Added 276.67%	1,468,240 $26.6 Million
Q4 2024 Feb 14, 2025	BUY	$23.31 - $32.4 $5.2 Million - $7.23 Million	223,200 Added 133.98%	389,797 $9.85 Million
Q3 2024 Nov 14, 2024	BUY	$32.06 - $44.56 $192,392 - $267,404	6,001 Added 3.74%	166,597 $5.66 Million
Q2 2024 Aug 13, 2024	SELL	$32.76 - $42.56 $3.14 Million - $4.08 Million	-95,752 Reduced 37.35%	160,596 $5.94 Million
Q1 2024 May 13, 2024	BUY	$35.22 - $51.88 $3.46 Million - $5.1 Million	98,256 Added 62.15%	256,348 $10.8 Million
Q4 2023 Feb 09, 2024	BUY	$22.61 - $40.65 $3.1 Million - $5.56 Million	136,897 Added 645.89%	158,092 $6.27 Million
Q3 2023 Nov 09, 2023	BUY	$25.45 - $37.46 $519,638 - $764,858	20,418 Added 2627.8%	21,195 $583,000
Q2 2023 Aug 11, 2023	SELL	$30.29 - $38.28 $1.82 Million - $2.3 Million	-60,098 Reduced 98.72%	777 $26,000
Q1 2023 May 12, 2023	SELL	$34.78 - $47.43 $2.03 Million - $2.77 Million	-58,368 Reduced 48.95%	60,875 $2.19 Million
Q4 2022 Feb 08, 2023	BUY	$27.78 - $45.38 $2.29 Million - $3.74 Million	82,315 Added 222.91%	119,243 $5.31 Million
Q3 2022 Nov 10, 2022	SELL	$22.7 - $37.57 $847,845 - $1.4 Million	-37,350 Reduced 50.28%	36,928 $1.04 Million
Q2 2022 Aug 10, 2022	SELL	$20.5 - $37.33 $1.77 Million - $3.23 Million	-86,501 Reduced 53.8%	74,278 $2 Million
Q1 2022 May 16, 2022	BUY	$27.64 - $39.32 $834,423 - $1.19 Million	30,189 Added 23.12%	160,779 $5.48 Million
Q4 2021 Feb 14, 2022	BUY	$35.68 - $56.27 $2.97 Million - $4.69 Million	83,264 Added 175.94%	130,590 $5.05 Million
Q3 2021 Nov 15, 2021	BUY	$28.95 - $55.99 $782,026 - $1.51 Million	27,013 Added 132.98%	47,326 $2.56 Million
Q2 2021 Aug 13, 2021	SELL	$20.71 - $35.37 $715,240 - $1.22 Million	-34,536 Reduced 62.97%	20,313 $679,000
Q1 2021 May 12, 2021	BUY	$16.19 - $29.91 $843,353 - $1.56 Million	52,091 Added 1888.72%	54,849 $1.13 Million
Q4 2020 Feb 11, 2021	BUY	$14.99 - $22.75 $17,808 - $27,027	1,188 Added 75.67%	2,758 $48,000
Q3 2020 Nov 12, 2020	BUY	$9.65 - $15.19 $9,457 - $14,886	980 Added 166.1%	1,570 $23,000
Q2 2020 Jul 31, 2020	SELL	$1.61 - $13.41 $494 - $4,116	-307 Reduced 34.23%	590 $7,000
Q1 2020 May 01, 2020	SELL	$1.55 - $3.07 $957 - $1,897	-618 Reduced 40.79%	897 $1,000
Q4 2019 Feb 14, 2020	SELL	$2.11 - $2.8 $6,819 - $9,049	-3,232 Reduced 68.09%	1,515 $3,000
Q3 2019 Nov 14, 2019	BUY	$2.05 - $2.75 $2,554 - $3,426	1,246 Added 35.59%	4,747 $10,000
Q2 2019 Aug 14, 2019	BUY	$2.43 - $5.09 $8,019 - $16,797	3,300 Added 1641.79%	3,501 $10,000
Q1 2019 May 14, 2019	BUY	$3.45 - $10.35 $693 - $2,080	201 New	201 $1,000

Others Institutions Holding CLDX

# of Institutions

199

Shares Held

68.2M

Call Options Held

219K

Put Options Held

238K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.27B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account